Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Jennifer Edelmann, MD PhD, Arran Dokal, MSc, PhD, Karlheinz Holzmann, Dr. rer. nat., David James Britton, BSc, PhD, Emma Vilventhraraja, MSc, PhD, Ryan Jack Smith, PhD, Mark S Cragg, Prof, Andrejs Braun, PhD, Hartmut Döhner, MD, Pedro Cutillas, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 1579.

https://doi.org/10.1182/blood-2019-128704

Published: 2019

Journal Articles

Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway

Jennifer Edelmann, MD, David James Britton, BSc, PhD, Emma Vilventhraraja, MSc, PhD, Arran Dokal, MSc, PhD, Karlheinz Holzmann, Dr. rer. nat., Mark C Cragg, Andrejs Braun, PhD, Pedro Cutillas, PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 588.

https://doi.org/10.1182/blood-2018-99-116490

Published: 2018

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Doriana DiBella, Emma Vilventhraraja, Stephen A Beers, PhD, Mark Cragg, PhD, Andrejs Braun, PhD, John G. Gribben, MDDSc FMedSci

Blood (2017) 130 (Supplement 1): 2996.

https://doi.org/10.1182/blood.V130.Suppl_1.2996.2996

Published: 2017

Journal Articles

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

Emma Vilventhraraja, Jennifer Edelmann, MD PhD, Faith Norster, Andrejs Braun, PhD, John G. Gribben, MDDSc FMedSci, Pedro Cutillas, PhD, Arran Dokal, MSc

Blood (2017) 130 (Supplement 1): 1269.

https://doi.org/10.1182/blood.V130.Suppl_1.1269.1269

Published: 2017

Journal Articles

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

Emma Vilventhraraja, Tetyana Klymenko, PhD, Jennifer Edelmann, MD, John Gribben, Andrejs Ivanov, PhD

Blood (2016) 128 (22): 1763.

https://doi.org/10.1182/blood.V128.22.1763.1763

Published: 2016

Journal Articles

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Jennifer Edelmann, MD, Tetyana Klymenko, PhD, Chen Lu, PhD, Emma Vilventhraraja, Sven Estenfelder, Eugen Tausch, Stephen A Beers, PhD, Stephan Stilgenbauer, Mark S Cragg, PhD, Andrejs Ivanov, PhD, John Gribben

Blood (2016) 128 (22): 971.

https://doi.org/10.1182/blood.V128.22.971.971

Published: 2016

Journal Articles

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 365.

https://doi.org/10.1182/blood.V126.23.365.365

Published: 2015

Journal Articles

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Blood (2014) 124 (21): 1938.

https://doi.org/10.1182/blood.V124.21.1938.1938

Published: 2014

Journal Articles

Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Veronica Teleanu, MD, Jennifer Edelmann, MD, Claudia Haferlach, MD, Stefan Ibach, Eugen Tausch, MD, Johannes Bloehdorn, MD, Veronique Leblond, MD PhD, Florence Cymbalista, MD, Alain Delmer, MD PhD, Michael Hallek, MD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 2184.

https://doi.org/10.1182/blood.V124.21.2184.2184

Published: 2014

Journal Articles

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

Jennifer Edelmann, MD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Thorsten Zenz, MD, Kirsten Fischer, MD, Jasmin Bahlo, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1964.

https://doi.org/10.1182/blood.V124.21.1964.1964

Published: 2014

Journal Articles

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Jennifer Edelmann, MD, Jenny Saub, Stefan Ibach, Karlheinz Holzmann, PhD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Daniel Mertens, PhD, Thorsten Zenz, MD, Florence Cymbalista, MD, Veronique Leblond, MD PhD, Alain Delmer, MD PhD, John G. Gribben, MD DSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3288.

https://doi.org/10.1182/blood.V124.21.3288.3288

Published: 2014

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 710.

https://doi.org/10.1182/blood.V120.21.710.710

Published: 2012

Journal Articles

Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,

Michael W.M. Kühn, MD, Lars Bullinger, Jennifer Edelmann, MD, Jan Krönke, MD, Gröschel Stefan, MD, Frank G. Rücker, Peter Paschka, MD, Verena I. Gaidzik, MD, Karlheinz Holzmann, PhD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner, MD

Blood (2011) 118 (21): 3546.

https://doi.org/10.1182/blood.V118.21.3546.3546

Published: 2011

Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 3609.

https://doi.org/10.1182/blood.V116.21.3609.3609

Published: 2010

Journal Articles

High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations

Blood (2010) 116 (21): 849.

https://doi.org/10.1182/blood.V116.21.849.849

Published: 2010

Journal Articles

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Jennifer Edelmann, MD, Karlheinz Holzmann, PhD, W.M. Michael Kühn, MD, Lars Bullinger, MD, Ina Radtke, MD, PhD, Xiaoping Su, PhD, Jing Ma, Ph.D., Dirk Winkler, MD, Andreas Buehler, Michael Hallek, M.D., James R. Downing, MD, Stephan Stilgenbauer, MD, Hartmut Doehner, MD

Blood (2010) 116 (21): 50.

https://doi.org/10.1182/blood.V116.21.50.50

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only